Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT PACE + Rituxan and Tandem Autologous Transplant for Waldenstrom's Macroglobulinemia
NCT00107614Phase 2Terminated
- Sponsor
- University of Arkansas
- Start
- Nov 2002
- Primary completion
- Feb 2008
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide in Waldenstrom macroglobulinemia (WM), sponsored by University of Arkansas. Started Nov 2002; status: terminated.
02
Drugs
dexamethasonethalidomidecisplatindoxorubicincyclophosphamide
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00107614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107614.